Related Experiment Videos
[Tissue polypeptide antigen as a biological marker of malignant pleural mesothelioma]
T Tokuyama1, Y Okamoto, K Hamada
1Second Department of Internal Medicine, Nara Medical University, Kashihara, Japan.
Abstract:
To evaluate the role of tissue polypeptide antigen (TPA) as a biological marker of malignant pleural mesothelioma (MPM), we used immunohistochemical techniques to detect TPA in tumor cells, and we measured the content of TPA in serum from patients with MPM. In 14 of 16 patients with MPM, TPA was detected in the cytoplasm of tumor cells. Epithelial-type cells from 11 of 12 patients were stained positively (91.7%), and sarcomatous-type cells from 7 of 8 patients were stained positively (87.5%). Serum TPA levels were abnormally high in 7 of 9 patients. Two of three patients with stage-I disease had normal serum TPA levels, and all patients whose disease was at stage II or higher had abnormal serum TPA levels. Serum TPA levels increased as MPM progressed. These results suggest that the serum TPA level can be used as a biological marker of MPM.
Insights
Tissue polypeptide antigen (TPA) shows promise as a biomarker for malignant pleural mesothelioma (MPM). Elevated serum TPA levels correlate with disease progression, aiding in MPM diagnosis and monitoring.
Area of Science:
- Oncology
- Biochemistry
Context:
- Malignant pleural mesothelioma (MPM) diagnosis can be challenging.
- Identifying reliable biomarkers is crucial for early detection and management.
Purpose:
- To investigate the utility of tissue polypeptide antigen (TPA) as a biological marker for MPM.
- To correlate TPA expression in tumor cells and serum levels with MPM staging and progression.
Summary:
- Immunohistochemistry detected TPA in the cytoplasm of tumor cells in 14/16 MPM patients (epithelial: 91.7%, sarcomatous: 87.5%).
- Abnormally high serum TPA levels were observed in 7/9 patients.
- Serum TPA levels were normal in early-stage (Stage I) disease but elevated in Stage II or higher, increasing with MPM progression.
Impact:
- Serum TPA levels demonstrate potential as a non-invasive biomarker for MPM diagnosis and prognosis.
- This finding may lead to improved monitoring strategies for patients with malignant pleural mesothelioma.